Evidence map›Paper›PMID 33802928›Full record

ArticleInternational journal of molecular sciences2021

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus.

Dawid Polak, Marcin Talar, Nina Wolska, Dagmara W Wojkowska, Kamil Karolczak, Karol Kramkowski, Tomasz A Bonda, Cezary Watala, Tomasz Przygodzki

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Dawid PolakDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Marcin TalarDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0001-8685-1161
Nina WolskaDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0002-8982-9741
Dagmara W WojkowskaDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0002-9317-9817
Kamil KarolczakDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.
Karol KramkowskiDepartment of Physical Chemistry, Medical University of Bialystok, Mickiewicza 2A, 15-089 Bialystok, Poland.
Tomasz A BondaDepartment of General and Experimental Pathology, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.ORCID 0000-0001-8735-1572
Cezary WatalaDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0002-5627-7872
Tomasz PrzygodzkiDepartment of Haemostasis and Haemostatic Disorders, Chair of Biomedical Sciences, Medical University of Lodz, Mazowiecka 6/8, 92-235 Lodz, Poland.ORCID 0000-0003-4937-8621
Medical University of Lodz · PLMedical University of Białystok · PL

Funding

Fundacja na rzecz Nauki Polskiej TEAM/2016-1/8
6 · The paper itself

Abstract

Blood platelets' adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y

Indexed as

Adenosine-5'-(N-ethylcarboxamide)Adenosine MonophosphateAdultAnimalsAntithrombinsBlood-Brain BarrierBlood PressureChloridesDiastoleFemaleFerric CompoundsFibrinogenHumansLaser-Doppler FlowmetryMaleMice2-hexynyladenosine-5'-N-ethylcarboxamideAdenosine-5'-(N-ethylcarboxamide)Adenosine MonophosphateAntithrombinscangrelorChloridesferric chlorideFerric CompoundsFibrinogenPrasugrel HydrochloridePurinergic P1 Receptor AgonistsPurinergic P2Y Receptor Antagonistsadenosine receptorsanimal modelsP2Y12 inhibitorsplateletsthrombosis

Identifiers

PMID33802928
PMCPMC8002731
OpenAlexW3136862509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.